Abstract:Aeromonas hydrophila, an uncommon human pathogen, can cause invasive infections in immunocompromised individuals. As the fluoroquinolones have been shown to be active in vitro against mesophilic aeromonads and clinical experience with the use of fluoroquinolones to treat aeromonads infections is limited, the antimicrobial activities of five selected drugs (ciprofloxacin, gatifloxacin, levofloxacin, lomefloxacin, and moxifloxacin) against A. hydrophila were studied in vitro and in mice. The MICs of the fluoroquinolones (except lomefloxacin), cefotaxime, and minocycline for 90% of 64 clinical isolates of A. hydrophila tested by the agar dilution method were <or=1 microg/ml. With a clinical cefotaxime-resistant strain, Ah 2743, in an in vitro time-kill study, at an inoculum of 7 x 10(5) CFU/ml incubated with fluoroquinolones, cefotaxime, or minocycline at concentrations equal to twice the MICs, the inhibitory effect lasted for less than 6 h and regrowth occurred thereafter. In an animal model with female BALB/c mice intraperitoneally infected with an inoculum of 1.1 x 10(7) CFU of Ah 2743, more mice in the ciprofloxacin-treated group survived (72.2%) than in the cefotaxime-, minocycline-, or cefotaxime-minocycline-treated group (P < 0.00001, log rank test). However, there were similar fatality rates, ranging from 71.4 to 87.5%, among mice treated with any of five fluoroquinolones. With a larger inoculum, 4.9 x 10(7) CFU, mice in the ciprofloxacin-treated group survived longer than those in the minocycline-, cefotaxime-, or cefotaxime-minocycline-treated group (30 h versus 18, 12, and 12 h, respectively [P < 0.002, log rank test]). However, in mice infected with cefotaxime-susceptible Ah 2556, ciprofloxacin was as effective as cefotaxime-minocycline. Thus, our results suggest that ciprofloxacin is at least as effective as cefotaxime-minocycline against murine A. hydrophila infections, which warrants clinical studies to delineate its role in human infections.

In Vitro and in Vivo Antibacterial Activities of Tosufloxacin Nanoemulsion

In vitro and in vivo activity of tosufloxacin

In Vivo Antibacterial Activity of Chinfloxacin, A New Fluoroquinolone Antibiotic

Preparation of Ceftiofur Nanoemulsion and Its Antimicrobial Effect on Major Pathogenic Bacteria of Bovine Mastitis

Preparation of Erythromycin Nanoemulsion and Determination of Its Bacteriostatic Activity in vitro

Combined systems of different antibiotics with nano-CuO against Escherichia coli and the mechanisms involved

In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin Against Escherichia Coli in a Neutropenic Murine Thigh Infection Model.

Antibacterial Effect of Furacilin Combination Nanoemulsion on the Main Pathogenic Bacteria of Bovine Endometritis in Vitro

The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium

The In-Vitro Sustained Effects of Antofloxacin Hydrochloride against Staphylococcus Aureus and Escherichia Coli

Preparation and Quality Evaluation of Tilmicosin Nanoemulsion

A Versatile Nanoemulsion of Antibiotic and Eucalyptol with Synergistic Effects Against E. Coli Infected Urocystitis

An Alternative Approach Using Nano-garlic Emulsion and its Synergy with Antibiotics for Controlling Biofilm-Producing Multidrug-Resistant Salmonella in Chicken

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate.

In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila

Tea tree oil nanoliposomes: optimization, characterization, and antibacterial activity against Escherichia coli in vitro and in vivo

In vitro activity of cefminox and comparators against Escherichia coli, Klebsiella pneumoniae and Bacteroides species

Pharmacokinetics/pharmacodynamics of Antofloxacin Hydrochloride in a Neutropenic Murine Thigh Model Ofstaphylococcus Aureusinfection

In Vitro Antibacterial Activity of Cefminox

Synthesis and in Vitro Antibacterial Activity of a Series of Novel Gatifloxacin Derivatives.

In vitro antibacterial activity study of gemifloxacin mesylate for injection